United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.55, $0.24 better than the analyst estimate of $2.31. Revenue for the quarter came in at $347.2 million versus the consensus estimate of $360.41 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.